Your birth certificate tells one story. Your cells tell another. While chronological age counts calendar years, biological age measures the cumulative wear on your body's systems—DNA methylation patterns, inflammatory markers, organ function—that predict how long you will live and how well. The gap between the two determines your health trajectory, and unlike the passage of time, biological age is modifiable.
What is biological age and how does it differ from chronological age?
Biological age quantifies physiological decline using biomarkers that correlate with disease risk, mortality, and functional capacity. Chronological age is fixed; biological age fluctuates based on genetics, environment, behavior, and medical interventions. A 50-year-old with optimal metabolic health, low inflammation, and preserved organ reserve may have a biological age of 42, while another 50-year-old with chronic stress, poor sleep, and metabolic syndrome may measure biologically as 58. The difference matters: biological age predicts cardiovascular events, cancer incidence, cognitive decline, and all-cause mortality independent of chronological age. Levine et al. 2018 demonstrated that individuals with accelerated biological aging face significantly higher mortality risk even after adjusting for traditional risk factors. We assess biological age as a core component of our Longevity Medicine programme because it shifts the clinical conversation from reactive disease management to proactive lifespan and healthspan optimization.
How do we measure biological age: GrimAge, PhenoAge, and DunedinPACE
Three principal clocks dominate clinical biological age assessment, each with distinct methodologies and predictive strengths. GrimAge, developed by Lu et al. 2019, uses DNA methylation patterns at 1,030 CpG sites to estimate mortality and healthspan. It incorporates surrogates for smoking pack-years and plasma protein levels, making it the strongest predictor of time-to-death and time-to-coronary heart disease among epigenetic clocks. GrimAge acceleration of five years correlates with a 20% increase in mortality risk. Its weakness: heavy reliance on smoking-related methylation changes means non-smokers with other risk factors may not show expected acceleration.
PhenoAge, from Levine et al. 2018, combines nine clinical biomarkers—albumin, creatinine, glucose, C-reactive protein, lymphocyte percent, mean cell volume, red cell distribution width, alkaline phosphatase, and white blood cell count—with chronological age. It predicts all-cause mortality, physical function, cognitive decline, and facial aging. PhenoAge is accessible (standard bloodwork) and captures systemic physiological state, but it reflects current health status more than deep biological trajectory and can be confounded by acute illness.
DunedinPACE (Pace of Aging, Computed from the Epigenome), published by Belsky et al. 2022, measures the rate of biological aging rather than biological age itself. Trained on 20 years of longitudinal data from the Dunedin Study tracking organ function decline, DunedinPACE quantifies how many years of biological aging occur per calendar year. A PACE of 1.2 means you are aging 20% faster than average; 0.8 means 20% slower. It is the most sensitive to intervention effects and predicts cognitive decline, physical limitations, and perceived age from facial photographs. Its limitation: it requires specialized methylation arrays not yet universally available.
We interpret all three in context. GrimAge anchors mortality prediction, PhenoAge reflects current systemic health, and DunedinPACE tracks whether interventions are working. No single clock is definitive; convergence across multiple measures provides confidence.
What interventions have real evidence for slowing biological aging
Intervention data is strongest for cardiovascular fitness. A 2018 study in the European Heart Journal found that VO₂max—maximal oxygen uptake during exercise—inversely correlates with biological age acceleration measured by DNA methylation. Every 1 mL/kg/min increase in VO₂max corresponded to approximately one year reduction in GrimAge. High-intensity interval training (HIIT) and sustained aerobic exercise improve mitochondrial function, reduce oxidative stress, and modulate inflammation. We prioritize VO₂max testing and structured exercise prescriptions because the dose-response is measurable and reproducible.
Sleep architecture, not just duration, influences biological age. Carroll et al. 2017 demonstrated that short sleep duration (<6 hours) and poor sleep efficiency accelerate epigenetic aging by 1.5–2 years. Deep sleep (slow-wave sleep) drives glymphatic clearance, growth hormone secretion, and immune regulation—all critical for cellular repair. We assess sleep with actigraphy and, when indicated, polysomnography, because subjective sleep reports often miss fragmentation and apnea.
Nutritional patterns with longevity signals include caloric restriction, time-restricted eating, and Mediterranean dietary patterns. The CALERIE trial showed 25% caloric restriction over two years reduced PhenoAge by approximately 0.11 years per month of intervention, though adherence remains challenging. Time-restricted eating (16:8 or 18:6) improves insulin sensitivity and autophagy without requiring calorie counting. Mediterranean diet adherence correlates with longer telomeres and lower inflammatory markers, as shown in Crous-Bou et al. 2014. We individualize nutritional interventions based on metabolic phenotype, not blanket prescriptions.
Stress mitigation with measurable physiological endpoints matters more than generic mindfulness. Epel et al. 2009 found that women with high perceived stress had telomeres equivalent to a decade of additional aging. Interventions that lower cortisol—structured meditation, cognitive behavioral therapy, HRV biofeedback—show modest but consistent effects. We track heart rate variability and salivary cortisol patterns to guide stress interventions, not self-reported anxiety scores alone.
The honest position on metformin and rapamycin for longevity
Metformin, a biguanide used for type 2 diabetes, shows promise in observational studies. The Bannister et al. 2014 analysis found diabetics on metformin had lower mortality than matched non-diabetics, suggesting longevity benefits beyond glucose control. Proposed mechanisms include AMPK activation, mitochondrial efficiency, and reduced mTOR signaling. The TAME trial (Targeting Aging with Metformin), led by Nir Barzilai, is testing metformin in non-diabetics aged 65–79 for aging outcomes, with results expected by 2026. Current evidence supports metformin use in those with prediabetes or metabolic syndrome, not as a blanket anti-aging drug. Off-label use in metabolically healthy individuals is speculative.
Rapamycin (sirolimus), an mTOR inhibitor, extends lifespan in every model organism tested—yeast, worms, flies, mice—by 20–30%. Mannick et al. 2014 showed low-dose rapamycin (0.5 mg daily, 1 mg daily, or 5 mg weekly) improved immune response to influenza vaccine in elderly adults, suggesting functional immune rejuvenation. Concerns include immunosuppression risk, glucose dysregulation, and lack of long-term human safety data at longevity doses. We do not prescribe rapamycin for longevity outside of clinical trial protocols. Patients seeking it should understand they are participating in an uncontrolled experiment, and we refer interested individuals to established research cohorts like the Participatory Evaluation of Aging with Rapamycin for Longevity Study (PEARL).
Why we integrate biological age testing into Longevity Medicine
Biological age moves the clinical paradigm from symptom-driven reactive care to trajectory-driven proactive optimization. A 45-year-old with accelerated GrimAge by seven years is not sick today but is on track for earlier disease onset. Early detection enables intervention before irreversible damage. We measure baseline biological age via PhenoAge (routine labs) and GrimAge (methylation array via commercial partners like TruDiagnostic), repeat annually, and adjust interventions based on delta. The goal is not immortality; it is maximizing the years lived without disability, pain, or dependence. Crimmins 2015 defines healthspan as years free from chronic disease—the true outcome longevity medicine targets. Biological age quantifies whether we are moving that number in the right direction.
